Abstract: The invention relates to crystalline forms of (6aR,10aR)-1-Hydroxy-6, 6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid (ajulemic acid), including pharmaceutical compositions comprising a crystalline form of ajulemic acid and methods of making a crystalline form of ajulemic acid. The invention also relates to the use of pharmaceutical compositions comprising a crystalline form of ajulemic acid for the treatment of disease, including inflammatory diseases and fibrotic diseases.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: Disclosed is an LED light source photocatalytic tubular reactor and application thereof. The LED light source photocatalytic tubular reactor comprises an LED light source, a temperature control chamber and a transparent reaction pipeline; the transparent reaction pipeline is located in the temperature control chamber; at least one side of the temperature control chamber is a light-transmitting plate; the LED light source provides a light source for the transparent reaction pipeline through the light-transmitting plate; and the transparent reaction pipeline has a diameter-to-length ratio of the inner diameter to the length of 0-0.1, but not 0. The LED light source continuous photocatalytic tubular reactor of the present disclosure can eliminate the scaling up effect, increase the yield and allow continuous production with an advantage of easy to use and low cost.

Abstract: The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Abstract: The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Abstract: The present invention is directed to crystal and amorphous forms of the 5-HT1A receptor antagonist 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride, as well as compositions thereof and methods of using the same.

Abstract: The present invention provides, among other things, forms of a compound of formula 1. In some embodiments, the present invention provides salt forms and/or crystal forms. In some embodiments, the present invention provides solid forms. The present invention also provides methods of making and using provided forms.

Abstract: Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4?-fluoro-2?-oxo-1?,2?-dihydrospiro[cyclopropane-1,3?-indol]-5?-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate.

Abstract: The present invention relates to one or more crystalline forms and polymorphs of compounds of formula I: in the form of pharmaceutically acceptable salts. The present invention is directed to crystalline polymorphs and forms of specific anilino-pyrimidine benzenesulfonamide compounds of formula I as pharmaceutically acceptable salts.

Abstract: The present invention relates to methods for preparing and manufacturing a crystalline form or polymorph of a compound of formula I: in the form of pharmaceutically acceptable salts and polymorphs thereof. The present invention is directed to methods for preparing and manufacturing crystalline polymorphs or forms of specific anilino-pyrimidine benzenesulfonamide compounds. Methods for converting one crystalline form or polymorph of compounds of formula I as their pharmaceutically acceptable salt polymorph to other different crystalline polymorphs of compounds of formula I as their corresponding pharmaceutically acceptable salt are also disclosed.

Abstract: The present invention relates to methods for preparing one or more crystalline forms and polymorphs of a compound of formula I: and structurally related compounds. The present invention is also directed to methods for converting one polymorph to other different polymorphs of formula I and structurally related compounds.

Abstract: The present invention relates to methods for preparing one or more crystalline polymorphs of a compound of formula I: and structurally related compounds. The present invention is also directed to methods for converting one polymorph to other different polymorphs of formula I and structurally related compounds.

Abstract: This invention relates to crystalline polymorphs of (3S)-N-hydroxy4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide, and preparation and uses thereof.

Abstract: A polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form III are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. Also provided are methods for preparing polymorph Form I of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile from polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile.

Abstract: A polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form II are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. Further provided are methods for preparing polymorph Form I of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile from polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile.

Abstract: Novel polymorphs, pharmaceutical compositions containing novel polymorphs, methods of using novel polymorphs and methods of preparing novel polymorphs of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)-1H-indol-3-yl](oxo)acetic acid are described herein.

Abstract: The present invention is directed to an anhydrate crystal form (designated as Form B herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Abstract: The present invention is directed to an anhydrate crystal form (designated as Form E herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Abstract: The present invention is directed to a hydrate crystal form (designated as Form F herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.